**Guideline-Directed Medical Therapy in Heart Failure (6.16.25)**

August 4, 2025 – December 31, 2025

**Error! Unknown op code for conditional.**

**Target Audience**

Specialties – Emergency Medicine, Family Medicine, Medicine, Neurology, Obstetrics & Gynecology, Radiological Sciences, Other

**Activity Objectives**

1 Identify the key components of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) and emerging clinical approaches to patients with heart failure with preserved ejection fraction (HFpEF).

2 Differentiate between the classes of medications used in GDMT and their mechanisms of action.

3 Apply evidence-based strategies to initiate, titrate, and monitor GDMT in clinical practice.

4 Evaluate the benefits and risks of GDMT in special populations.

5 Incorporate the most recent ACC/AHA/HFSA guideline updates into the management of patients with heart failure.

**Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and UC Berkeley.  The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Enduring Material for a maximum of 0.75 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.



A close-up of a sign

AI-generated content may be incorrect.

ABIM
CME
MOC
Accredited

ABIM
CME
MOC
Accredited

CME for
ABPath CC

Part 2
MOC
The American Board of Pediatrics

**MOC Statement(s)**

ABIM
CME
MOC
AccreditedSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ABMS

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sarah Epstein, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Hattie Hanley, Other | Course Director | Nothing to disclose - 10/23/2024 |
| Nathan D. Wong, PhD, MPH | Planning Commitee Member | Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Grant or research support-Novo Nordisk (Any division) (Relationship has ended)|Consulting Fee-Heart Lung|Grant or research support-Amgen, Inc.|Speakers Bureau-Novartis Corporation Pharmaceuticals - 01/06/2025 |
| Jan Hirsch, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Cindy Giambrone, PharmD | Activity Coordinator | Stocks or stock options, excluding diversified mutual funds-Sanofi S.A.|Stocks or stock options, excluding diversified mutual funds-Abbott (Any division) - 02/12/2025 |
| William Bommer, MD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Michelle Kittleson, MD, PhD | Faculty | Nothing to disclose - 07/07/2025 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.